1 “... with treatment with SoC, ixekizumab has an incremental cost-utility ratio (ICUR) of $113,023 per quality-adjusted...”

2 “... with treatment with SoC, ixekizumab has an incremental cost-utility ratio (ICUR) of $113,023 per quality-adjusted...”